CGRP function‐blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat
Authors:
Open Access
- 1 December 2008
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 155 (7) , 1093-1103
Abstract
Background and purpose: Calcitonin gene‐related peptide (CGRP) receptor antagonists effectively abort migraine headache and inhibit neurogenic vasodilatation in humans as well as rat models. Monoclonal antibodies typically have long half‐lives, and we investigated whether or not function‐blocking CGRP antibodies would inhibit neurogenic vasodilatation with a long duration of action and therefore be a possible approach to preventive therapy of migraine. During chronic treatment with anti‐CGRP antibodies, we measured cardiovascular function, which might be a safety concern of CGRP inhibition.Experimental approach: We used two rat blood flow models that measure electrically stimulated vasodilatation in the skin or in the middle meningeal artery (MMA). These vasomotor responses are largely dependent on the neurogenic release of CGRP from sensory afferents. To assess cardiovascular function during chronic systemic anti‐CGRP antibody treatment, we measured heart rate and blood pressure in conscious rats.Key results: Treatment with anti‐CGRP antibodies inhibited skin vasodilatation or the increase in MMA diameter to a similar magnitude as treatment with CGRP receptor antagonists. Although CGRP antibody treatment had a slower onset of action than the CGRP receptor antagonists, the inhibition was still evident 1 week after dosing. Chronic treatment with anti‐CGRP antibodies had no detectable effects on heart rate or blood pressure.Conclusions and implications: We showed for the first time that anti‐CGRP antibodies exert a long lasting inhibition of neurogenic vasodilatation in two different rat models of arterial blood flow. We have provided strong preclinical evidence that anti‐CGRP antibody may be a suitable drug candidate for the preventive treatment of migraine.British Journal of Pharmacology (2008) 155, 1093–1103; doi:fn4; published online 8 September 2008Keywords
This publication has 54 references indexed in Scilit:
- CGRP-Receptor Antagonists — A Fresh Approach to Migraine Therapy?New England Journal of Medicine, 2004
- Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: Tailored-SELEXNucleic Acids Research, 2003
- Effects of BIBN4096BS on cardiac output distribution and on CGRP-induced carotid haemodynamic responses in the pigEuropean Journal of Pharmacology, 2003
- Cgrp May Play A Causative Role in MigraineCephalalgia, 2002
- Elevated Sympathetic Nervous Activity in Mice Deficient in αCGRPCirculation Research, 2001
- Functional Role of α-Calcitonin Gene-Related Peptide in the Regulation of the Cardiovascular SystemThe Journal of Pharmacology and Experimental Therapeutics, 2001
- Role of opioid receptors in neurogenic dural vasodilation and sensitization of trigeminal neurones in anaesthetized ratsBritish Journal of Pharmacology, 2001
- Neurogenic inflammation in the context of migraineMicroscopy Research and Technique, 2001
- Increased Blood Pressure in α-Calcitonin Gene–Related Peptide/Calcitonin Gene Knockout MiceHypertension, 2000
- Mice Lacking α-Calcitonin Gene-Related Peptide Exhibit Normal Cardiovascular Regulation and Neuromuscular DevelopmentMolecular and Cellular Neuroscience, 1999